Complete remission of lupus nephritis with rituximab and steroids for induction and rituximab alone for maintenance therapy

Details

Serval ID
serval:BIB_CD425C453CD6
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Complete remission of lupus nephritis with rituximab and steroids for induction and rituximab alone for maintenance therapy
Journal
Am J Kidney Dis
Author(s)
Camous L., Melander C., Vallet M., Squalli T., Knebelmann B., Noel L. H., Fakhouri F.
ISSN
1523-6838 (Electronic)
ISSN-L
0272-6386
Publication state
Published
Issued date
08/2008
Volume
52
Number
2
Pages
346-52
Language
english
Notes
Camous, Laurent
Melander, Catherine
Vallet, Marion
Squalli, Tarek
Knebelmann, Bertrand
Noel, Laure-Helene
Fakhouri, Fadi
eng
Case Reports
Am J Kidney Dis. 2008 Aug;52(2):346-52. doi: 10.1053/j.ajkd.2008.03.036. Epub 2008 Jun 24.
Abstract
Lupus nephritis (LN) is a severe and frequent complication of systemic lupus erythematosus. For decades, cyclophosphamide-based regimens have been the gold standard in treating patients with LN. However, cyclophosphamide use is associated with increased morbidity and mortality, and thus alternative treatments are needed. We report 3 cases of severe class IV LN successfully treated with rituximab as an induction, as well as a long-term maintenance, treatment. Complete remission of LN, documented by means of a control kidney biopsy, occurred in all patients and was maintained during follow-up using rituximab as sole maintenance treatment. No severe infectious complications were observed during treatment with rituximab. Our data suggest that rituximab may prove to be an optimal maintenance treatment in patients with severe LN.
Keywords
Adult, Antibodies, Monoclonal/administration & dosage/*therapeutic use, Antibodies, Monoclonal, Murine-Derived, Biopsy, Cell Proliferation, Dose-Response Relationship, Drug, Drug Therapy, Combination, Follow-Up Studies, Glucocorticoids/administration & dosage/*therapeutic use, Humans, Immunologic Factors/administration & dosage/*therapeutic use, Infusions, Intravenous, Kidney/pathology, Lupus Nephritis/*drug therapy/pathology, Microscopy, Fluorescence, Remission Induction, Rituximab, Severity of Illness Index, Time Factors
Pubmed
Create date
01/03/2022 10:18
Last modification date
02/03/2022 6:36
Usage data